title: Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study.
abstract: 53 patients with squamous cell carcinoma of the head and neck recurrent after initial treatment were entered into a phase II trial of the epirubicin, methotrexate and bleomycin (EMB) combination. The primary objective of the study was to evaluate the activity of this combination. Compliance to EMB and the possible non-cross-resistance to previous cisplatin-containing chemotherapy were secondary objectives. In order to avoid patient selection bias, the study involved randomisation between EMB and a cisplatin-methotrexate-bleomycin (DMB) combination (with EMB: DMB = 2:1). 23 out of 53 (43% +/- 13) EMB patients showed an objective response, lasting a median of 12 (range 4-39) weeks; interestingly, 5 out of 14 (36% +/- 25) patients pretreated with cisplatin plus 5-fluorouracil responded to EMB. The treatment compliance was good and a median of three courses was delivered. No patient refused the treatment after the initial cycle. Leukopenia (47%) and oral mucositis (42%) were the main side effects. DMB produced a response rate of 33% +/- 18 with a median duration of 5 (4-13) weeks. None of the patients previously treated with cisplatin plus 5-fluorouracil responded. 5 patients refused the treatment after the first cycle and a median of two cycles (0-5) was delivered. In conclusion, EMB produced results similar to cisplatin-containing regimens, with a mild to moderate toxicity and a good compliance; the possible non cross-resistance with cisplatin plus 5-fluorouracil deserves further evaluation.
authors.affiliation: Divisione di Oncologia Medica, ULSS N. 21, Padova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Paccagnella
authors.forename: G L
authors.initials: GL
authors.lastname: Pappagallo
authors.forename: R
authors.initials: R
authors.lastname: Segati
authors.forename: P
authors.initials: P
authors.lastname: Zorat
authors.forename: G
authors.initials: G
authors.lastname: Cavaniglia
authors.forename: F
authors.initials: F
authors.lastname: Lunghi
authors.forename: V
authors.initials: V
authors.lastname: Migliorini
authors.forename: A
authors.initials: A
authors.lastname: Frattina
authors.forename: A
authors.initials: A
authors.lastname: Bianco
authors.forename: V C
authors.initials: VC
authors.lastname: Sileni
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011379:Prognosis
chemical_list: D001761:Bleomycin; D015251:Epirubicin; D008727:Methotrexate